The causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic is the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This
Researchers probe intriguing interaction between sugars and the SARS-CoV-2 spike protein
Home ยป
Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape
The current pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered an
Researchers reveal novel therapeutic target in the treatment of certain cancers
Mount Sinai Researchers Find "Removal of AKAP11 Protein by Autophagy as a key to Fuel Mitochondrial Metabolism and Tumor Cell
Researchers reveal novel therapeutic target in the treatment of certain cancers
Mount Sinai Researchers Find "Removal of AKAP11 Protein by Autophagy as a key to Fuel Mitochondrial Metabolism and Tumor Cell
SARS-CoV-2 variants with E484K mutation show mRNA vaccine-induced antibody evasion
A recent study by researchers in Switzerland found that the Pfizer-BioNTech mRNA vaccine had limited efficacy in identifying mutated receptor-binding
Why does convalescent plasma therapy for severe COVID-19 show mixed success?
Treatment modalities against the coronavirus disease 2019 (COVID-19) pandemic are limited in efficacy. This has led many centers to use
Why does convalescent plasma therapy for severe COVID-19 show mixed success?
Treatment modalities against the coronavirus disease 2019 (COVID-19) pandemic are limited in efficacy. This has led many centers to use
Natural virus-induced immunity protective against UK and South African SARS-CoV-2 variants in hamster study
As new variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge, fueling the continued spread of
How a receptor shapes the immune response
Researchers led by Professor Carolyn King of the University of Basel have developed a method to study the specialization of
Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five